BIVI - BioVie Inc. Stock Price, Fair Value and News

0.49USD-0.01 (-2.00%)Delayed as of 17 May 2024, 01:53 pm ET

Market Summary

USD0.49-0.01

Delayedas of 17 May 2024, 01:53 pm

-2.00%

BIVI Stock Price

View Fullscreen

BIVI RSI Chart

BIVI Valuation

Market Cap

30.5M

Price/Earnings (Trailing)

-0.84

Price/Sales (Trailing)

38.4

Price/Free Cashflow

-0.87

BIVI Price/Sales (Trailing)

BIVI Profitability

Return on Equity

-191.76%

Return on Assets

-114.22%

Free Cashflow Yield

-115.46%

BIVI Fundamentals

BIVI Revenue

Revenue (TTM)

794.4K

Rev. Growth (Yr)

161.84%

Rev. Growth (Qtr)

-52.83%

BIVI Earnings

Earnings (TTM)

-36.3M

Earnings Growth (Yr)

46.36%

Earnings Growth (Qtr)

3.97%

Breaking Down BIVI Revenue

52 Week Range

0.497.63

(Low)(High)

Last 30 days

2.0%

Last 90 days

-59.3%

Trailing 12 Months

-93.0%

How does BIVI drawdown profile look like?

BIVI Financial Health

Current Ratio

2.45

Debt/Equity

Debt/Cashflow

-563.62

BIVI Investor Care

Shares Dilution (1Y)

68.19%

Diluted EPS (TTM)

-0.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	152.8K	239.0K	659.7K	794.4K
2022	40.2K	44.1K	78.0K	149.6K
2021	0	22.0K	28.8K	35.6K
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioVie Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	do cuong v	bought	-	-	10,000	president & ceo
Dec 11, 2023	kim joanne wendy	acquired	-	-	5,000	chief financial officer
Dec 01, 2023	gorlin steve	sold	-127,899	1.69	-75,680	-
Nov 30, 2023	do cuong v	bought	17,800	1.78	10,000	president & ceo
Nov 09, 2023	rogich sigmund	acquired	-	-	42,254	-
Nov 09, 2023	hariri robert j	acquired	-	-	42,254	-
Nov 09, 2023	gorlin steve	acquired	-	-	46,358	-
Nov 09, 2023	berman richard j	acquired	-	-	51,830	-
Sep 05, 2023	gorlin steve	sold	-26,108	3.05	-8,560	-
Aug 22, 2023	berman richard j	sold	-37,827	3.5009	-10,805	-

Which funds bought or sold BIVI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	SHEPHERD KAPLAN KROCHUK, LLC	unchanged	-	-21,540	15,567	0.01%
May 15, 2024	STATE STREET CORP	reduced	-0.33	-128,842	92,594	-%
May 15, 2024	MORGAN STANLEY	reduced	-70.37	-91,607	13,005	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-3.76	-27,408	18,524	-%
May 15, 2024	BARCLAYS PLC	reduced	-36.68	-16,000	6,000	-%
May 15, 2024	Rockbridge Investment Management, LCC	sold off	-100	-378	-	-%
May 15, 2024	Altium Capital Management LP	new	-	1,592,460	1,592,460	0.63%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-731	529	-%
May 15, 2024	SABBY MANAGEMENT, LLC	new	-	364,277,000	364,277,000	0.21%
May 15, 2024	Tower Research Capital LLC (TRC)	added	68.85	-2,668	6,498	-%

Are Funds Buying or Selling BIVI?

Are funds buying BIVI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIVI

No. of Funds

Unveiling BioVie Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 10, 2023	acuitas group holdings, llc	71.91%	30,435,738	SC 13D/A
Mar 07, 2023	acuitas group holdings, llc	87.0%	30,438,938	SC 13D/A
Aug 16, 2022	acuitas group holdings, llc	84.8%	30,438,938	SC 13D/A
Jul 15, 2022	acuitas group holdings, llc	78.2%	19,529,846	SC 13D/A
Jun 11, 2021	peizer terren s	87.5%	19,529,846	SC 13D/A
May 10, 2021	peizer terren s	80.0%	11,168,538	SC 13D/A
Apr 27, 2021	peizer terren s	80.0%	11,168,538	SC 13D/A
Sep 23, 2020	peizer terren s	80.3%	11,168,538	SC 13D/A

Recent SEC filings of BioVie Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
Apr 19, 2024	8-K	Current Report
Apr 05, 2024	UPLOAD	UPLOAD
Mar 15, 2024	CORRESP	CORRESP
Mar 13, 2024	UPLOAD	UPLOAD
Mar 11, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	8-K/A	Current Report
Mar 04, 2024	8-K	Current Report

Peers (Alternatives to BioVie Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

BioVie Inc. News

Latest updates

BioVie Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q2	2019Q1	2019Q1
Revenue	-100.0%	-	218	462	98.00	17.00	83.00	42.00	11.00	13.00	12.00	8.00	8.00	9.00	1,340	2,671	4,002	5,334	6,665	-	-	-
Operating Expenses	-11.9%	7,732	8,781	10,876	10,977	13,775	11,495	8,834	9,292	5,749	6,665	5,547	131,603	3,002	3,063	387	577	699	710	656	848	-
S&GA Expenses	-12.4%	1,974	2,254	1,943	2,620	2,520	4,405	2,007	3,362	2,114	1,894	2,395	282	2,155	2,068	228	391	289	307	323	459	-
R&D Expenses	-11.9%	5,700	6,470	8,876	8,300	11,197	7,033	6,770	5,873	3,577	4,714	3,095	621	790	938	101	128	353	347	276	332	-
Interest Expenses	-23.4%	629	821	1,005	1,108	1,083	1,053	1,056	927	919	316	1.00	-	-	143*	559	1,240	34.00	21.00	1*	1*	-
Net Income	4.0%	-8,067	-8,401	-10,710	-9,111	-15,041	-15,687	-10,415	-8,088	-7,040	-5,414	-5,540	-131,532	-2,992	-3,057	7,334	-19,154	-366	6,665	-655	-848	-
Net Income Margin	16.1%	-45.68*	-54.46*	-76.63*	-210.26*	-322.16*	-275.64*	-396.82*	-591.76*	-3.72	-4.09	-4.98	-5.93	-	-	-	-	-	-	-	-	-
Free Cashflow	1.0%	-5,851	-5,909	-12,177	-11,287	-11,735	-8,009	-9,220	-5,865	-5,884	-4,706	-2,534	-7,008	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q2
Assets	47.8%	32.00	21.00	24.00	35.00	45.00	47.00	23.00	20.00	26.00	32.00	22.00	6.00	13.00	13.00	15.00	2.00	2.00	2.00	3.00	3.00	3.00
Current Assets	48.5%	31.00	21.00	23.00	34.00	44.00	46.00	22.00	19.00	25.00	31.00	21.00	5.00	11.00	12.00	13.00	0.00	1.00	1.00	1.00	1.00	1.00
Cash Equivalents	50.1%	30.00	20.00	21.00	19.00	31.00	46.00	21.00	19.00	25.00	30.00	20.00	5.00	11.00	0.00	13.00	0.00	0.00	0.00	0.00	0.00	1.00
Goodwill	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-8.2%	13.00	14.00	16.00	20.00	23.00	21.00	17.00	16.00	16.00	16.00	2.00	1.00	1.00	9.00	16.00	24.00	5.00	4.00	11.00	0.00	0.00
Current Liabilities	-10.7%	12.00	14.00	13.00	14.00	16.00	8.00	4.00	4.00	4.00	4.00	1.00	1.00	1.00	0.00	0.00	24.00	5.00	4.00	11.00	0.00	0.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	-	-	-	-	-
Shareholder's Equity	152.6%	19.00	7.00	8.00	15.00	22.00	26.00	6.00	4.00	10.00	16.00	20.00	5.00	11.00	13.00	15.00	-	-	-	-	2.00	3.00
Retained Earnings	-2.8%	-329	-320	-311	-301	-292	-277	-261	-250	-242	-235	-230	-224	-93.35	-90.36	-87.30	-41.04	-21.88	-21.52	-28.18	-7.26	-6.61
Additional Paid-In Capital	6.2%	348	328	319	316	314	303	267	255	253	252	251	230	105	103	102	20.00	20.00	19.00	19.00	9.00	9.00
Shares Outstanding	53.0%	61.00	40.00	37.00	36.00	36.00	31.00	27.00	25.00	25.00	25.00	24.00	22.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	86.00	-	-	-	23.00	-	-	-	18.00	-	18.00	-	-	-	53.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	1.0%	-5,851	-5,909	-12,177	-11,287	-11,735	-8,009	-9,220	-5,865	-5,884	-4,706	-2,534	-7,008	-1,041	-1,319	-1,083	-360	-401	-275	-590	-631	-658
Share Based Compensation	-	691	-	808	742	18.00	18.00	879	1,803	930	1,147	1,927	679	804	1,537	-	-	14.00	11.00	-	2.00	44.00
Cashflow From Investing	-	-	-	14,525	-1,796	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	224.6%	15,975	4,922	-594	1,268	9,768	32,527	11,810	-	-	14,610	18,511	169	517	-	14,242	394	402	30.00	500	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIVI Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
OPERATING EXPENSES:
Amortization	$ 57,344	$ 57,344	$ 172,033	$ 172,033
Research and development expenses	5,700,447	11,196,835	21,046,369	24,999,665
Selling, general and administrative expenses	1,974,264	2,520,330	6,170,883	8,931,957
TOTAL OPERATING EXPENSES	7,732,055	13,774,509	27,389,285	34,103,655
LOSS FROM OPERATIONS	(7,732,055)	(13,774,509)	(27,389,285)	(34,103,655)
OTHER (INCOME) EXPENSE:
Change in fair value of derivative liabilities	(109,003)	366,093	(1,799,339)	4,154,645
Interest expense	628,711	1,082,762	2,453,979	3,192,631
Interest income	(183,933)	(182,201)	(864,186)	(307,055)
TOTAL OTHER (INCOME) EXPENSE, NET	335,775	1,266,654	(209,546)	7,040,221
NET LOSS	(8,067,830)	(15,041,163)	(27,179,739)	(41,143,876)
Deemed dividend related to ratchet adjustment to warrants	886,423		886,423
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (8,954,253)	$ (15,041,163)	$ (28,066,162)	$ (41,143,876)
NET LOSS PER COMMON SHARE
- Basic	$ (0.20)	$ (0.43)	$ (0.70)	$ (1.32)
- Diluted	$ (0.20)	$ (0.43)	$ (0.70)	$ (1.32)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
- Basic	44,801,084	35,325,580	39,869,913	31,217,382
- Diluted	44,801,084	35,325,580	39,869,913	31,217,382
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (8,954,253)	$ (15,041,163)	$ (28,066,162)	$ (41,143,876)
Other comprehensive (loss) income
Unrealized gain on investments for available-for-sale		16,505		16,505
Reclassification of unrealized gains on available-for-sale investments upon settlement			(176,591)
Total other comprehensive (loss) income		16,505	(176,591)	16,505
Comprehensive loss	$ (8,954,253)	$ (15,024,658)	$ (28,242,753)	$ (41,127,371)

BIVI Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Jun. 30, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 30,350,337	$ 19,460,883
Investments in U.S. Treasury Bills		14,477,726
Prepaids and other current assets	189,582	102,526
Total current assets	30,539,919	34,041,135
Operating lease right-of-use assets, net	422,169	80,789
Intangible assets, net	465,062	637,095
Goodwill	345,711	345,711
TOTAL ASSETS	31,772,861	35,104,730
CURRENT LIABILITIES:
Accounts payable and accrued expenses	4,409,754	3,476,259
Other current liabilities		48,385
Current portion of operating lease liabilities	57,143	44,909
Current portion of note payable, net of financing cost, unearned premium and discount of $492,905 at March 31, 2024 and $894,926 at June 30, 2023	7,992,904	9,105,074
Warrant liabilities	20,703	894,280
Embedded derivative liability		925,762
Total current liabilities	12,480,504	14,494,669
Operating lease liabilities, net of current portion	366,430	42,505
Note payable, net of current portion, financing cost, unearned premium and discount of $0 and $227,270 at March 31, 2024 and June 30, 2023, respectively.		5,227,270
TOTAL LIABILITIES	12,846,934	19,764,444
STOCKHOLDERS' EQUITY:
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2024 and June 30, 2023, respectively; 61,018,606 shares issued of which 60,969,846 shares are outstanding at March 31, 2024; and 36,451,829 shares issued of which 36,428,949 shares outstanding at June 30, 2023;	6,115	3,643
Additional paid in capital	348,211,684	316,385,759
Accumulated other comprehensive income		176,591
Accumulated deficit	(329,291,867)	(301,225,705)
Treasury stock	(5)	(2)
Total stockholders' equity	18,925,927	15,340,286
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 31,772,861	$ 35,104,730

About BioVie Inc.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

CEO	Mr. Cuong Viet Do M.B.A., MBA
WEBSITE	https://bioviepharma.com
INDUSTRY	Biotechnology
EMPLOYEES	18

BioVie Inc. Frequently Asked Questions

What is the ticker symbol for BioVie Inc.? What does BIVI stand for in stocks?

BIVI is the stock ticker symbol of BioVie Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioVie Inc. (BIVI)?

As of Thu May 16 2024, market cap of BioVie Inc. is 30.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIVI stock?

You can check BIVI's fair value in chart for subscribers.

What is the fair value of BIVI stock?

You can check BIVI's fair value in chart for subscribers. The fair value of BioVie Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioVie Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIVI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioVie Inc. a good stock to buy?

The fair value guage provides a quick view whether BIVI is over valued or under valued. Whether BioVie Inc. is cheap or expensive depends on the assumptions which impact BioVie Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIVI.

What is BioVie Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, BIVI's PE ratio (Price to Earnings) is -0.84 and Price to Sales (PS) ratio is 38.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIVI PE ratio will change depending on the future growth rate expectations of investors.